Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study Meeting Abstract

  

Authors:	Jhawer, M.; Kindler, H. L.; Wainberg, Z.; Ford, J.; Kunz, P.; Tang, L.; McCallum, S.; Kallender, H.; Shah, M. A.
Abstract Title:	Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study
Meeting Title:	45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	27
Issue:	15 Suppl.
Meeting Dates:	2009 May 29-Jun 2
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2009-05-20
Start Page:	202s
Language:	English
ACCESSION:	WOS:000276606603094
PROVIDER:	wos
DOI:	10.1200/jco.2009.27.15_suppl.4502
Notes:	Meeting Abstract: 4502 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129661